

Oxford Nanopore Technologies plc

("Oxford Nanopore" or the "Group")

Full Year Trading Update and Notice of Results

12 January 2026

Strong 2025 performance; full year revenue growth slightly ahead of guidance

- The Group expects to report revenue of approximately £223 - £224 million (FY24: £183.2 million), representing growth of approximately 22% on a reported basis and 24% at constant currency, slightly ahead of the Group's guidance range of 20-23% constant currency growth.
- Continued progress on path to profitability.

Broad-based growth across all geographies, customer end markets and product categories

- Continued commercial momentum with revenue growth increasing by more than 20% constant currency across each region (EMEA1, APAC and AMR).
- Across customer end markets, Clinical revenue grew by approximately 60% on a reported basis, BioPharma by approximately 30% and Applied Industrial by approximately 27%. Research revenue grew by approximately 15% during the period despite end-market funding pressures.¹
- Growth was delivered across all product types, led by the PromethION range, which grew by more than 40% year-on-year on a reported basis.

Business remains well capitalised to deliver on its goals

- Oxford Nanopore ended the year with approximately £302 million in cash, cash equivalents and other liquid investments as at 31 December 2025 (FY24: £403.8 million), ahead of consensus expectations helped by improving working capital, providing continued balance sheet strength to support execution of the Group's strategy.

Notice of Results

- Oxford Nanopore will announce its preliminary annual results for the twelve months ended 31 December 2025 on Monday 2 March 2026.
- Management will host a virtual presentation on the same day at 9:30am GMT / 4:30am EST, followed by a Q&A session accessible via webcast and conference call.

-ENDS-

This trading update is based upon unaudited management accounts and has been prepared solely to provide additional information on trading to the shareholders of Oxford Nanopore Technologies plc. All figures are provisional and subject to further review.

For further information, please contact:

Oxford Nanopore Technologies plc

Investors: ir@nanoporetech.com

Media: media@nanoporetech.com

Teneo (communications adviser to the Company)

Tom Murray, Jo Blackshaw

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com

Notes:

(1) The FY24 customer end market comparatives have been re-presented following a refinement of the data categorisation during the year. There has been no change to the overall FY24 revenue number however there has been a reclassification of £1.9 million from Applied Industrial and £1.0 million from BioPharma to the Research (£1.6 million) and Clinical (£1.3 million) markets.

- Constant currency (CC) applies the same rate to the FY25 and FY24 non-GBP results based on FY24 rates.
- All percentages compare to the equivalent 2024 period.
- APAC: Asia Pacific, AMR: The Americas, EMEA: Europe, the Middle East, Africa and India

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Group has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.

For more information please visit: www.nanoporetech.com

Forward-looking statements

This announcement contains certain forward-looking statements. For example, statements regarding expected revenue growth and profit margins are forward-looking statements. Phrases such as "aim", "plan", "expect", "intend", "anticipate", "believe", "estimate", "target", and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business and financial performance and financial condition, and by definition address matters that are, to different degrees, uncertain. Our results could be affected by macroeconomic conditions, delays or challenges in manufacturing or delivering of products to our customers, suspensions of large projects and/or acceleration of large products or accelerated adoption of pathogen surveillance or applied uses of our products. These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TSTGUGDBLUBDGLD